Biotech | August 18, 2021
ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
KIMS Hospitals' brand, has an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The transaction is expected to close in the Q4FY22
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Aditya Puri former MD of HDFC bank joins Solara board as chairman
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
